Edgar Filing: PDL BIOPHARMA, INC. - Form 4

Form 4	IARMA, INC.							
July 24, 200				OMB AF	PROVAL			
FORM	UNITED STATE	CS SECURITIES AND EXCHANGE Washington, D.C. 20549	COMMISSION	OMB Number:	3235-0287			
Check th if no lon subject t Section	ger STATEMENT (OF CHANGES IN BENEFICIAL OW SECURITIES	NGES IN BENEFICIAL OWNERSHIP OF					
Section 16.SECONTIESburden hours per responseForm 4 orForm 5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,0.5Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19400.5								
(Print or Type	Responses)							
	Address of Reporting Person <u>*</u> RICHARD /CA/	2. Issuer Name and Ticker or Trading Symbol PDL BIOPHARMA, INC. [PDLI]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
	(First) (Middle) IOPHARMA, I CAMPUS DRIVE	3. Date of Earliest Transaction (Month/Day/Year) 07/20/2007	_X_ Director _X_ Officer (give below)	X_ Director 10% Owner X Officer (give title Other (specify				
	(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)						
FREMONT, CA 94555 — Form filed by More than One Reporting Person								
(City)	(State) (Zip)	Table I - Non-Derivative Securities Ac	quired, Disposed of,	, or Beneficial	y Owned			
1.Title of Security (Instr. 3)	any	eemed 3. 4. Securities Acquired ion Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) n/Day/Year) (Instr. 8) (A) or Code V Amount (D) Price	Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)				
Common Stock	07/20/2007	F $\frac{1,519}{(1)}$ D $\frac{$}{25.93}$	51,606	D				

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	 6. Date Exercisable and actionNumber Expiration Date of (Month/Day/Year) 8) Derivative Securities Acquired (A) or Disposed of (D) 		ate	7. Titl Amou Under Securi (Instr.	int of lying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(Instr. 3, 4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: PDL BIOPHARMA, INC. - Form 4

Reporting Owners

Reporting Owner Name / Address							
	Director	10% Owner	Officer	Other			
MURRAY RICHARD /CA/ C/O PDL BIOPHARMA, INC. 34801 CAMPUS DRIVE FREMONT, CA 94555	Х		EVP & CSO				
Signatures							
/s/ Francis Sarena by Francis Sa Murray	07/24/2007						

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents the number of shares withheld by the issuer and canceled to satisfy tax withholding obligations of the reporting person that arose in connection with the vesting of restricted shares of common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.